Abbott and MSD Pharmaceuticals have entered into partnership for distribution of oral anti-diabetic medicines in India. Under a distribution agreement, Abbott will distribute the oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version of MSD Pharmaceuticals (MSD) in India. MSD's sitagliptin, its combination and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Abbott will leverage its broad in-country footprint to continue to make these medicines available to people in India.
Sitagliptin is a Dipeptidyl Peptidase IV Inhibitor (DPP4i) used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008.
Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: